Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy
J Clin Oncol
.
2019 Nov 10;37(32):2961-2967.
doi: 10.1200/JCO.19.01595.
Epub 2019 Sep 10.
Authors
David J VanderWeele
1
,
Emmanuel S Antonarakis
2
,
Michael A Carducci
2
,
Robert Dreicer
3
,
Karim Fizazi
4
,
Silke Gillessen
5
,
Celeste S Higano
6
,
Alicia K Morgans
1
,
Daniel P Petrylak
7
,
Christopher J Sweeney
8
,
Maha Hussain
1
Affiliations
1
Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL.
2
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD.
3
University of Virginia Cancer Center, Charlottesville, VA.
4
Institut Gustave Roussy, University of Paris Sud, Villejuif, France.
5
Manchester Cancer Research Centre, Manchester, United Kingdom.
6
Fred Hutchinson Cancer Research Center, Seattle, WA.
7
Yale University School of Medicine, New Haven, CT.
8
Dana-Farber Cancer Institute, Boston, MA.
PMID:
31498754
DOI:
10.1200/JCO.19.01595
No abstract available
MeSH terms
Clinical Trials, Phase III as Topic
Decision Making*
Humans
Male
Neoplasm Metastasis
Practice Patterns, Physicians'
Precision Medicine / methods
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy*